Uncategorized

4/25/18: PHASE 3 IMMUNOTHERAPY STUDY SHOWS PROMISE IN ADVANCED NON-SMALL-CELL LUNG CANCER: Patients Who Received Keytruda® With Chemo Lived Longer Than Those Getting Chemo Alone — Ann G. Sjoerdsma

The big news in cancer research last week was the release of clinical trial results showing that patients with advanced non-small-cell lung cancer (NSCLC) who received an immunotherapy drug plus standard chemotherapy as first-line treatment lived “significantly” longer than NSCLC patients who received only chemotherapy. In the new Phase 3 trial, led by Dr. Leena […]

via 4/25/18: PHASE 3 IMMUNOTHERAPY STUDY SHOWS PROMISE IN ADVANCED NON-SMALL-CELL LUNG CANCER: Patients Who Received Keytruda® With Chemo Lived Longer Than Those Getting Chemo Alone — Ann G. Sjoerdsma

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s